References
- Bocher A, Hagmann F, Kreiter H. Chronic ITP. Current therapy concept and introduction to pathophysiologic, clinical and diagnostic aspects. Med Clin 1998;93(12):707–718.
- Bussel J, Wissert M, Oates B, et al. Humanized monoclonal anti-CD40L antibody rescue therapy of 15 adults with severe chronic refractory ITP. Blood 1999;94:646a.
- Cines D, McMillan R. Management of adult ITP. Ann Rev Med 2005;56(1):425–442.
- Fan Y, Ge Y, Zhu H, et al. Characterization and application of two novel McAbs against CD40L: Epitope and functional studies on cell membrane CD40L and studies on the origin of soluble serum CD40L. Tissue Antigens 2004;64(3):257–263.
- George J, Raskob G, Bussel J, et al. Safety and effect on platelet count of repeated doses of McAb to CD40L in patients with chronic ITP. Blood 1999;94:19a.
- George J, Raskob G, Lichtin A, et al. Safety and effect on platelet count of single-dose McAb to CD40L in patients with ITP. Blood 1998;92:707a.
- Hayashi S, Oshida M, Kiyokawa T, et al. Determination of activated platelets: Evaluation of methodology and application for patients with ITP. Rinsho Byori 2001;49(12):1287–1292.
- Kooten C, Banchereau J. CD40—CD4OL. J Leucoc Biol 2000; 67(1):2–17.
- Kuwana M. Advances in immunological aspects of ITP. Nippon Rinsho 2003;61(4):670–675.
- Kuwana M, Nomura S, Fujimura K, et al. Effect of a single injection of humanized anti-CD154 McAb on the platelet-specific autoimmune response in patients with ITP. Blood 2004;103(4):1229–1236.
- Kuwana M, Kawakami Y, Ikeda Y. Suppression of autoreactive T cell response to glycoprotein Hb/IIIa by blockade of CD40/CD154 interaction: Implications for treatment of ITP. Blood 2003;101(2):621–623.
- Kuwana M, Kawakami Y, Ikeda Y. Recent topics on basic research for ITP. Rinsho Byori 2001a;49(10):992–995.
- Kuwana M, Kaburaki J, Kitasato H, et al. Immunodominant epitopes on GPIIb/IIIa recognized by autoreactive T cells in patients with ITP. Blood 2001b;98(1):130–139.
- Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in ITP: Role in production of anti-platelet autoantibody. J Clin Invest 1998;102:1393–1402.
- Nagahama M, Nomura S, Kanazawa S, et al. Significance of chemokines and sCD4OL in patients with ITP. Eur J Hematol 2002;69(5-6):303–308.
- Nishimura S, Ishida T, Imai K. McAb therapy for disorders of hemostasis and coagulation. Nippon Rinsho 2002;60(3): 525–530.
- Nomura S, Kuwana M, Ikeda Y. Induction of T cell tolerance in a patient with ITP by single injection of humanized McAb to CD4OL. Autoimmunity 2003;36(5) :317–319.
- Ogawara H, Handa H, Morita K, et al. High Th1/Th2 ratio in patients with chronic ITP. Eur J Hematol 2003;71(4): 283–288.
- Porcelijn L, von dem Borne A. Immune-mediated thrombo-cytopenias: Basic and immunological aspects. Chin Hematol 1998;11(2) :331–341.
- Pusiol A, Cesaro S, Nocerino A, et al. Successful treatment with the McAb rituximab in two children with refractory autoimmune thrombocytopenia. Eur J Pediatr 2004;163(6): 305–307.
- Sandler S. Review: ITP: An update for immunohematologists. Immunohematol 2004;20 (2): 112–117 .
- Sandler S, Tutuncuoglu S. ITP-current management prac-tices. Expert Opin Pharmacother 2004;5(12):2515–2527.
- Shouxi S, Kuwana M, Ikeda Y. Anti-CD4OL: Biology and therapy in ITP. J Chin Invest 2004;14(3):11–14.
- Sidiropoulos P, Boumpas D. Lessons learned from anti-CD4OL treatment in SLE patients. Lupus 2004;13(5): 391–397.
- Solanilla A, Pasquet J, Viallard J, et al. Platelet-associated CD154 in ITP. Blood 2005;105(1):215–218.
- Tomer A, Koziol J, McMillan R. Autoimmune thrombocyto-penia: Flow cytometric determination of platelet-associated autoantibodies against platelet specific receptors. J Thromb Hemost 2005;3(1):74–78.
- Webber N, Mascarenhas J, Crow M, et al. Functional properties of lymphocytes in ITP. Hum Immunol 2001;62(12): 1346–1355.
- Zhao Y, Gao Q Cheng Y, et al. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with ITP. Zhonghua Xue Ye Xue Za Zhi 2003;24(9):474–476.